These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25785148)

  • 21. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transurethral resection of the bladder tumour (TURBT) for non-muscle invasive bladder cancer: basic skills.
    Furuse H; Ozono S
    Int J Urol; 2010 Aug; 17(8):698-9. PubMed ID: 20649827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
    Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
    BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor.
    Lee SE; Jeong IG; Ku JH; Kwak C; Lee E; Jeong JS
    Urology; 2004 May; 63(5):873-7; discussion 877. PubMed ID: 15134968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When to Avoid a Restaging Procedure for Non-muscle Invasive Bladder Cancer? Inferences from a Tertiary Care Center.
    Bhirud DP; Mittal A; Kumar S; Narain TA; Kishore S; Navriya SC; Ranjan SK; Panwar VK
    Indian J Surg Oncol; 2022 Sep; 13(3):604-611. PubMed ID: 36187522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method.
    Miyake M; Nishimura N; Nakai Y; Fujii T; Owari T; Hori S; Morizawa Y; Gotoh D; Anai S; Torimoto K; Tanaka N; Hirao Y; Fujimoto K
    Diagnostics (Basel); 2021 Jan; 11(2):. PubMed ID: 33525423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group.
    Yuk HD; Kim JK; Jeong CW; Kwak C; Kim HH; Ku JH
    Biomed Res Int; 2018; 2018():9432606. PubMed ID: 30271788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of preoperative platelet-related parameters and plasma fibrinogen in patients with non-muscle invasive bladder cancer after transurethral resection of bladder tumor.
    Song Y; Tian J; Yang L; Zhang Y; Dong Z; Ding H; Wang J; Wang Y; Wang H; Wang Z
    Future Oncol; 2022 Aug; 18(26):2933-2942. PubMed ID: 35880441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The intravesical recurrence after 3-day consecutive intravesical instillation of pirarubicine hydrochloride (THP) following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer].
    Tochigi T; Sakurada Y; Aoki H; Kawamura S; Itou S; Satou I; Tateno H
    Nihon Hinyokika Gakkai Zasshi; 2012 Jul; 103(4):610-6. PubMed ID: 23120995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the safety and efficiency of conventional monopolar, plasmakinetic, and holmium laser transurethral resection of primary non-muscle invasive bladder cancer.
    Xishuang S; Deyong Y; Xiangyu C; Tao J; Quanlin L; Hongwei G; Jibin Y; Dongjun W; Zhongzhou H; Jianbo W; Lina W; Lin Y
    J Endourol; 2010 Jan; 24(1):69-73. PubMed ID: 19954353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: A comparative study from experienced institutes.
    Miyake M; Nishimura N; Nakahama T; Nishimoto K; Oyama M; Matsushita Y; Miyake H; Fukuhara H; Inoue K; Kobayashi K; Matsumoto H; Matsuyama H; Fujii T; Hirao Y; Fujimoto K
    BJUI Compass; 2023 May; 4(3):305-313. PubMed ID: 37025476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeat transurethral resection is still an essential tool in treating non-muscle invasive bladder cancer: the Western Australian experience.
    Chang DTS; Picardo A
    Bladder (San Franc); 2020; 7(2):e42. PubMed ID: 32775484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer.
    Zapała P; Dybowski B; Poletajew S; Białek Ł; Niewczas A; Radziszewski P
    World J Surg Oncol; 2018 Jan; 16(1):6. PubMed ID: 29334958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
    Cumberbatch MGK; Foerster B; Catto JWF; Kamat AM; Kassouf W; Jubber I; Shariat SF; Sylvester RJ; Gontero P
    Eur Urol; 2018 Jun; 73(6):925-933. PubMed ID: 29523366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re-transurethral resection treatment for non-invasive bladder tumor.
    Han CH; Shi Z; Xuan X; Chen B; Dong B; Hao L; Qiu X; Zhou X; Wu TL; Liu D
    Cell Biochem Biophys; 2014 Jul; 69(3):589-92. PubMed ID: 24500837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer.
    Ali MH; Ismail IY; Eltobgy A; Gobeish A
    J Endourol; 2010 Dec; 24(12):2047-50. PubMed ID: 20929433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bladder cancer local staging about muscle invasion: 3.0T MRI performance following transurethral resection].
    Zhao SM; Yang TJ; Xu CM; Guo XF; Ma YK; Chen XJ; Li X; He CH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 52(4):701-704. PubMed ID: 32773805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence.
    Hu Z; Mudaliar K; Quek ML; Paner GP; Barkan GA
    Ann Diagn Pathol; 2014 Apr; 18(2):49-52. PubMed ID: 24370460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relook TURBT in superficial bladder cancer: its importance and its correlation with the tumor ploidy.
    Dwivedi US; Kumar A; Das SK; Trivedi S; Kumar M; Sunder S; Singh PB
    Urol Oncol; 2009; 27(5):514-9. PubMed ID: 18639472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer.
    Akand M; Muilwijk T; Raskin Y; De Vrieze M; Joniau S; Van Der Aa F
    Clin Genitourin Cancer; 2019 Aug; 17(4):e784-e792. PubMed ID: 31097388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.